The US Food and Drug Administration (FDA) has approved Boston Scientific’s Infinion 16 Percutaneous Lead for the company’s Precision Plus spinal cord stimulator system. Boston Scientific states that this is the first rechargeable spinal cord stimulator device for chronic pain management and its 16 Lead is the world’s first and only 16-contact percutaneous lead.
The company is introducing the Infinion 16 Lead at the North American Neuromodulation Society (NANS) meeting in Las Vegas, USA.
Spinal cord stimulation leads are designed to deliver electrical pulses from an implantable pulse generator to the spinal cord to mask pain signals to the brain. Until now, percutaneous leads have offered a maximum of eight stimulating contacts. By providing twice the number of contacts than any previous percutaneous lead, the Infinion 16 Lead is designed to offer more coverage of the spinal cord for the management of chronic pain.
“When a single percutaneous lead is the best choice for my patient, the Infinion 16 Lead is a useful new option that lets me cover more of the spinal cord than ever before,” said Marshall Bedder, director of Interventional Pain at Pacific Medical Centers in Seattle, USA. “For the first time, I can now place 16 contacts through a single, small insertion needle with just one lead placement.”